Cargando…
An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
BACKGROUND: Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary progressive (ORATORIO) multiple sclerosis (MS). These effects may be particularly important among patients with increased disa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079307/ https://www.ncbi.nlm.nih.gov/pubmed/32206332 http://dx.doi.org/10.1177/2055217320911939 |
_version_ | 1783507797400354816 |
---|---|
author | Wolinsky, Jerry S Engmann, Natalie J Pei, Jinglan Pradhan, Ashish Markowitz, Clyde Fox, Edward J |
author_facet | Wolinsky, Jerry S Engmann, Natalie J Pei, Jinglan Pradhan, Ashish Markowitz, Clyde Fox, Edward J |
author_sort | Wolinsky, Jerry S |
collection | PubMed |
description | BACKGROUND: Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary progressive (ORATORIO) multiple sclerosis (MS). These effects may be particularly important among patients with increased disability. OBJECTIVE: In this post hoc exploratory analysis, we evaluated the efficacy of ocrelizumab on disability progression among a subgroup of patients with MS who had increased baseline disability levels (Expanded Disability Status Scale scores ≥4.0) in the pivotal trials. METHODS: During the double-blind period, patients received ocrelizumab 600 mg intravenously every 24 weeks for 96 weeks in the OPERA trials (versus interferon β-1a 44 μg subcutaneously three times per week) and for 120 weeks in ORATORIO (versus placebo). Kaplan–Meier and Cox survival analyses were used to assess disability outcome measures. RESULTS: Baseline demographic, disease, and treatment characteristics were generally comparable across treatment groups in patients with increased disability from the OPERA and ORATORIO trials. Ocrelizumab treatment numerically, and in some instances significantly, reduced confirmed disability progression versus the comparator in these patients. CONCLUSIONS: In patients with increased baseline disability, ocrelizumab reduced the risk of confirmed disability progression versus interferon β-1a in patients with relapsing-onset MS and versus placebo in patients with progression-onset MS. |
format | Online Article Text |
id | pubmed-7079307 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-70793072020-03-23 An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability Wolinsky, Jerry S Engmann, Natalie J Pei, Jinglan Pradhan, Ashish Markowitz, Clyde Fox, Edward J Mult Scler J Exp Transl Clin Original Research Paper BACKGROUND: Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary progressive (ORATORIO) multiple sclerosis (MS). These effects may be particularly important among patients with increased disability. OBJECTIVE: In this post hoc exploratory analysis, we evaluated the efficacy of ocrelizumab on disability progression among a subgroup of patients with MS who had increased baseline disability levels (Expanded Disability Status Scale scores ≥4.0) in the pivotal trials. METHODS: During the double-blind period, patients received ocrelizumab 600 mg intravenously every 24 weeks for 96 weeks in the OPERA trials (versus interferon β-1a 44 μg subcutaneously three times per week) and for 120 weeks in ORATORIO (versus placebo). Kaplan–Meier and Cox survival analyses were used to assess disability outcome measures. RESULTS: Baseline demographic, disease, and treatment characteristics were generally comparable across treatment groups in patients with increased disability from the OPERA and ORATORIO trials. Ocrelizumab treatment numerically, and in some instances significantly, reduced confirmed disability progression versus the comparator in these patients. CONCLUSIONS: In patients with increased baseline disability, ocrelizumab reduced the risk of confirmed disability progression versus interferon β-1a in patients with relapsing-onset MS and versus placebo in patients with progression-onset MS. SAGE Publications 2020-03-16 /pmc/articles/PMC7079307/ /pubmed/32206332 http://dx.doi.org/10.1177/2055217320911939 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Paper Wolinsky, Jerry S Engmann, Natalie J Pei, Jinglan Pradhan, Ashish Markowitz, Clyde Fox, Edward J An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability |
title | An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability |
title_full | An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability |
title_fullStr | An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability |
title_full_unstemmed | An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability |
title_short | An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability |
title_sort | exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability |
topic | Original Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079307/ https://www.ncbi.nlm.nih.gov/pubmed/32206332 http://dx.doi.org/10.1177/2055217320911939 |
work_keys_str_mv | AT wolinskyjerrys anexploratoryanalysisoftheefficacyofocrelizumabinpatientswithmultiplesclerosiswithincreaseddisability AT engmannnataliej anexploratoryanalysisoftheefficacyofocrelizumabinpatientswithmultiplesclerosiswithincreaseddisability AT peijinglan anexploratoryanalysisoftheefficacyofocrelizumabinpatientswithmultiplesclerosiswithincreaseddisability AT pradhanashish anexploratoryanalysisoftheefficacyofocrelizumabinpatientswithmultiplesclerosiswithincreaseddisability AT markowitzclyde anexploratoryanalysisoftheefficacyofocrelizumabinpatientswithmultiplesclerosiswithincreaseddisability AT foxedwardj anexploratoryanalysisoftheefficacyofocrelizumabinpatientswithmultiplesclerosiswithincreaseddisability AT wolinskyjerrys exploratoryanalysisoftheefficacyofocrelizumabinpatientswithmultiplesclerosiswithincreaseddisability AT engmannnataliej exploratoryanalysisoftheefficacyofocrelizumabinpatientswithmultiplesclerosiswithincreaseddisability AT peijinglan exploratoryanalysisoftheefficacyofocrelizumabinpatientswithmultiplesclerosiswithincreaseddisability AT pradhanashish exploratoryanalysisoftheefficacyofocrelizumabinpatientswithmultiplesclerosiswithincreaseddisability AT markowitzclyde exploratoryanalysisoftheefficacyofocrelizumabinpatientswithmultiplesclerosiswithincreaseddisability AT foxedwardj exploratoryanalysisoftheefficacyofocrelizumabinpatientswithmultiplesclerosiswithincreaseddisability |